Hims & Hers Health (NYSE:HIMS – Get Free Report) had its target price cut by stock analysts at Barclays from $39.00 to $35.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 5.17% from the stock’s previous close.
A number of other brokerages also recently issued reports on HIMS. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research note on Tuesday, May 12th. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $32.17.
Get Our Latest Research Report on HIMS
Hims & Hers Health Stock Performance
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the company earned $0.17 earnings per share. The company’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health will post -0.05 EPS for the current fiscal year.
Insider Buying and Selling
In other Hims & Hers Health news, insider Soleil Boughton sold 25,111 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the sale, the insider directly owned 313,964 shares of the company’s stock, valued at $8,649,708.20. This represents a 7.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the completion of the sale, the chief financial officer directly owned 228,938 shares of the company’s stock, valued at $8,033,434.42. This trade represents a 19.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 186,769 shares of company stock valued at $6,035,648 over the last ninety days. 11.76% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Hims & Hers Health
A number of hedge funds have recently bought and sold shares of HIMS. Bank of America Corp DE grew its holdings in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Norges Bank purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $62,153,000. Invesco Ltd. increased its stake in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after acquiring an additional 1,600,004 shares during the period. Marex Group plc grew its stake in Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after acquiring an additional 1,496,707 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
- Meta Platform’s Legal Issues Could Become Much More Than A Q2 Earnings Headache
- Marvell Constructs an AI Moat With Alphabet Warrants
- Microsoft’s Sell-Off May Be a Gift, Not a Warning
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
